COMPARISON OF TWO INTRAGASTRIC BALLOON SYSTEMS FOR WEIGHT LOSS IN A CLINICAL SETTING

Michael C. Bennett[1], Dayna S. Early[1], Shelby A. Sullivan[2], Rachel E. Maday[1], Suzanne M. Bell[1], Daniel Mullady[1], Vladimir M. Kushnir[1]

1) Division of Gastroenterology, Washington University School of Medicine 2) Division of Gastroenterology, University of Colorado School of Medicine

Background

- Two intragastric balloons (IGB) have been FDA approved for weight loss in the United States.
  - ReShape Integrated Dual Balloon System (ReShape Medical, San Clemente, CA)
  - Orbera Intragastric Balloon (Apollo Endosurgery, Austin, TX).
- No head-to-head comparison of these devices has been reported. Our aim was to evaluate the efficacy and safety of the two systems in our practice.

Aim

- Compare efficacy of ReShape and Orbera IGBs in our practice

Methods

- Consecutive patients who underwent IGB placement and had a minimum of 20 weeks of follow up were included.
- The decision to place either the ReShape or the Orbera device was at the discretion of the patient.
- Following placement, patients were seen by a registered dietician and behavior coach every 2-4 weeks.
- Primary end point:
  - Total body weight loss at 20 weeks after IGB placement
- Secondary end point:
  - Adverse Events requiring IGB removal or urgent medical intervention (hospitalization or emergency room visit)

ReShape Integrated Dual Balloon System®



Orbera Intragastric Balloon®



Baseline Characteristics

	ReShape	Orbera	p value
Number placed	26	14	
Female	22 (85%)	14 (100%)	0.28
Age (years)	48.3±2.0	52.2±4.0	0.34
Weight (pounds)	225±9	248±11	0.13
BMI (kg/m^2)	36.5±1.2	40.8±1.8	0.05

Adverse Events

	ReShape	Orbera	p value
Nausea/vomiting	8 (31%)	6 (43%)	0.50
Reflux	8 (31%)	6 (43%)	0.50
Abdominal Pain	4 (15%)	3 (21%)	0.68
Adverse events requiring intervention	3 (12%)	6 (43%)	0.04
GI symptoms requiring ER visit/ admission	0	2	
Early Removal due to Intolerance	2	4	
Early Removal due to Deflation	1	0	

Total Body Weight Loss 20 Weeks Post-placement



Conclusions

- **In a post-approval U.S. clinical practice setting, efficacies of ReShape and Orbera IGB were similar, with a 10% total body weight loss at 20 weeks post placement**
- **Adverse events requiring intervention occurred significantly more often with the Orbera IGB**